CN106138486A - A kind of Chinese medicine preparation treating fungal keratitis - Google Patents
A kind of Chinese medicine preparation treating fungal keratitis Download PDFInfo
- Publication number
- CN106138486A CN106138486A CN201610664999.9A CN201610664999A CN106138486A CN 106138486 A CN106138486 A CN 106138486A CN 201610664999 A CN201610664999 A CN 201610664999A CN 106138486 A CN106138486 A CN 106138486A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- group
- medicine preparation
- folium
- fungal keratitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of Chinese medicine preparation treating fungal keratitis, belong to technical field of Chinese medicines.Inventor is for the pathogenesis of fungal keratitis, theory according to tcm treatment according to syndrome differentiation, selection has heat-clearing and toxic substances removing, invigorate blood circulation wind dispelling, liver heat removing and eyesight improving, the Chinese medicine Folium Lagerstroemiae Indicae of hard masses softening and resolving, Rhizoma Ligustici, Herba Arenariae Serpyllifoliae, Ramulus et Folium Psychotriae Serpentis, unrooted, Radix Glycyrrhizae, decocting becomes decoction, through clinical trial, total effective rate reaches 97.5%.
Description
Technical field
The present invention relates to technical field of Chinese medicines, particularly relate to a kind of Chinese medicine preparation treating fungal keratitis.
Background technology
Along with antibiotic and corticosteroid medication are in the extensive application of ophthalmology, fungal keratitis sickness rate substantially increases
Adding, the fungal species infecting cornea is various, and the toxicity that the fungus corneal of different strains infects is different, and clinical manifestation is the most different,
The most different to the curative effect of antifungal drug.At present, doctor trained in Western medicine curative effect in terms for the treatment of is undesirable, and toxic and side effects is big；We according to
Clinical experience for many years, uses treatment by Chinese herbs fungal keratitis, achieves preferable therapeutic effect, and treatment by Chinese herbs can promote to damage
Hinder revascularization, promote that phagocytic function is recovered；Having excited body effect, producing body stimulates, and strengthens nervous system
Excited process；The formation of collagen fiber and vitreous degeneration process can be reduced or reduce cellulose and ooze out, thus reduce cicatrix with
The formation of adhesion；The medicine making heat-clearing and toxic substances removing is easier to penetrate into local organization, makes drug absorption accelerate；Sanguimotor add
Speed, improves the metabolism of nutrition and material, thus the eliminating of beneficially pathological product, morbid substance.
Summary of the invention
It is an object of the invention to provide a kind of Chinese medicine preparation treating fungal keratitis.Research shows the poison of fungus itself
Power i.e. aggressivity and body defenses are the two big factors that fungal infection occurs extremely.The suitable heat-clearing and toxic substances removing of Chinese traditional treatment, wind dispelling of invigorating blood circulation,
Liver heat removing and eyesight improving, hard masses softening and resolving.
It is an object of the invention to be achieved through the following technical solutions, the Chinese medicine preparation of this treatment fungal keratitis be by
The Chinese medicine of following weight portion is made: Folium Lagerstroemiae Indicae 7-11 part, Rhizoma Ligustici 10-16 part, Herba Arenariae Serpyllifoliae 10-18 part, Ramulus et Folium Psychotriae Serpentis 30-40 part,
Unrooted 60-80 part, Radix Glycyrrhizae 10-16 part.
Preferred: Folium Lagerstroemiae Indicae 9 parts, Rhizoma Ligustici 13 parts, Herba Arenariae Serpyllifoliae 14 parts, Ramulus et Folium Psychotriae Serpentis 35 parts, unrooted 70 parts, Radix Glycyrrhizae 13
Part.
Preparation method: traditionally make decoction.
Fang Zhong: Folium Lagerstroemiae Indicae, Rhizoma Ligustici are monarch drug, are aided with Herba Arenariae Serpyllifoliae, unrooted is ministerial drug, and Ramulus et Folium Psychotriae Serpentis is adjuvant drug, and Radix Glycyrrhizae is
Make medicine.Folium Lagerstroemiae Indicae has preferable antifungic action, and the external Candida albicans bacteria concentration that kills is 8 mg/ml, to diphtheria corynebacterium etc.
Antibacterial also has effect, valid density 4 mg/ml；Rhizoma Ligustici dispersing wind and cold damp, decoct has inhibitory action to multiple fungus；Little nothing
Heart dish clearing away heat to improve acuity of vision, removing toxic substances；Ramulus et Folium Psychotriae Serpentis wind-damp dispelling, strengthening bone and muscle, alleviating pain and detumescence；Unrooted eliminating inflammation and expelling toxin；Radix Glycyrrhizae and middle emergency, profit
Lung removing toxic substances, coordinating the actions of various ingredients in a prescription.
Detailed description of the invention
Embodiment one: weigh Folium Lagerstroemiae Indicae 7g, Rhizoma Ligustici 10g, Herba Arenariae Serpyllifoliae 10g, Ramulus et Folium Psychotriae Serpentis 30g, unrooted 60g, Radix Glycyrrhizae
10g, traditionally makes decoction.
Embodiment two: weigh Folium Lagerstroemiae Indicae 9g, Rhizoma Ligustici 13g, Herba Arenariae Serpyllifoliae 14g, Ramulus et Folium Psychotriae Serpentis 35g, unrooted 70g, Radix Glycyrrhizae
13g, traditionally makes decoction.
Embodiment one: weigh Folium Lagerstroemiae Indicae 11g, Rhizoma Ligustici 16g, Herba Arenariae Serpyllifoliae 18g, Ramulus et Folium Psychotriae Serpentis 40g, unrooted 80g, Radix Glycyrrhizae
16g, traditionally makes decoction.
Toxicity test
1, laboratory animal cleaning grade healthy SD female rats 40, weight (185 ± 8) g, as chronic toxicity；
The female white mice in cleaning grade health Kunming 30, weight (28 ± 4) g, as acute toxicological experiment.Feed with normal diet, general
Logical drinking-water.Room temperature controls in (23 ± 3) DEG C, humidity (51 ± 4) %, natural lighting.
2, acute toxicological experiment is according to (Chinese medicine, researches on natural drugs registration service manual), selects cleaning grade health Kunming
Female white mice 30, is randomly divided into 2 groups, Chinese drug-treated group and each 15 of blank group.Chinese drug-treated group is administered orally 8g/d by adult normal
(being equivalent to crude drug 154g) is converted to the dosage of white mice, gavages Chinese medicine every day 1 time.Blank group gives 1mL/20g weight
0.9% sodium chloride injection gavages.
3, long term toxicity test cleaning grade healthy SD female rats 40, is randomly divided into 4 groups, Normal group and Chinese medicine
Group little, in, heavy dose of each 10.Matched group gives 1ml/20g weight 0.9% sodium chloride injection, Chinese drug-treated group little, in,
Heavy dose of group is that adult normal consumption is converted to the 5 of rat dosage, 15,50 times, i.e. 0.12g, 0.36g, 1.2g.Be gavage to
Medicine.Every day 1 time, experimental period is 3 months.
4, acute toxicity testing result white mice nothing in being administered 7d is dead, to observation post administration mice outward appearance, hair color, light
Pool is normal, and social behavior, reaction are all normal, ingests, drains normally.Manually put to death dissection after 7d, observe its heart, liver, spleen
Dirty, lungs, kidney, brain, ovary, uterus are showed no exception.Pathological examination: dyeing in single-minded Yihong of Lignum Sappan (HE), Chinese drug-treated group is dirty
Device smooth surface, in order, cell size, form are normal in organizational structure arrangement, and the dyeing of endochylema, karyon is clear, with blank group
Comparing difference not statistically significant (P ＞ 0.05).
5, chronic toxicity result Chinese drug-treated group little, in, heavy dose of group and the outward appearance of rats in normal control group, hair color,
Social behavior, zest etc. and to surrounding, food, the equal not statistically significant of comparing difference (P ＞ 0.05) such as interest of water.
(P ＜ 0.05) is increased before the experiment of weight the most relatively this group after 4 groups of rat experiments, but the equal nothing of weight comparing difference after 4 groups of experiments
Statistical significance (P ＞ 0.05), blood cytology index, blood biochemical analysis index, important organ coefficient ratio after 4 groups of rat experiments
Compared with the equal not statistically significant of difference (P ＞ 0.05).At 4 groups of rats, after death important organ row staining pathologic section checks, HE dyes,
In order, cell size, form are normal for the arrangement of Chinese drug-treated group Rats Organs and Tissues organizational structure, and the dyeing of endochylema, karyon is clear, with normal control
Group comparing difference not statistically significant (P ＞ 0.05).
Toxicity test shows, the Chinese medicine preparation of the treatment fungal keratitis of the present invention has no toxic reaction after being administered.
Clinical data
1, fungal keratitis patient 200 example that case selection selection of clinical is made a definite diagnosis, male 100 example, women 100 example, year
Age 22～65 years old, 40.5 years old mean age；On the basis of patient knows the inside story and be voluntary, patient is divided into 9 groups by us；Only take purple
Common vetch leaf single medicinal material group is A group, only take Rhizoma Ligustici single medicinal material group is B group, only takes Herba Arenariae Serpyllifoliae single medicinal material group and be C group, only take
Ramulus et Folium Psychotriae Serpentis single medicinal material group be D group, only take unrooted single medicinal material group be E group, only to take Radix Glycyrrhizae single medicinal material group be F group, takes this
Invention is treatment group by embodiment two preparation group, and employing routine treatment is matched group.Each group in age, sex, the course of disease, symptom
Light and heavy degree is basically identical, without significant difference, has comparability.
2, single medicinal material is traditionally made 4mg/ml by medicament selection A group, B group, C group, D group, E group, F group respectively；Control
After each Chinese herbal medicine is assorted by treatment group by part, traditionally make 4mg/ml；Each group every day 1 dose be 500ml, divides and takes for 2 times；Right
Use Chibroxin according to group, instill in eyelid, one time 1～2,3～6 times on the one, the course for the treatment of is depending on the state of an illness；Two groups equal
It was a course for the treatment of with 5 days, treats comparison therapy result after two courses for the treatment of.
3, efficacy determination (1) is cured: the irritation such as sensation of dryness, foreign body sensation all disappears, and eye recovers normal；(2) aobvious
Effect: the irritation such as sensation of dryness, foreign body sensation substantially alleviates, and eye is clearly better；(3) effective: sensation of dryness, foreign body sensation etc. stimulate disease
Shape has alleviated, and eye has taken a turn for the better；(4) invalid: by the irritation such as sensation of dryness, foreign body sensation after treatment without alleviating or adding
Weight.
4, the result after two courses for the treatment of is treated
| Group | Number of cases | Cure | Effective | Effectively | Invalid | Total effective rate (%) |
| Treatment group | 40 | 30 | 6 | 3 | 1 | 97.5 |
| Matched group | 40 | 15 | 6 | 8 | 11 | 72.5 |
| A | 20 | 1 | 2 | 0 | 17 | 15.0 |
| B | 20 | 0 | 1 | 1 | 18 | 10.0 |
| C | 20 | 0 | 1 | 0 | 19 | 5.0 |
| D | 20 | 0 | 1 | 1 | 18 | 10.0 |
| E | 20 | 0 | 2 | 0 | 18 | 10.0 |
| F | 20 | 0 | 1 | 0 | 19 | 5.0 |
The treatment that the therapeutic effect of Chinese medicine preparation of the present invention treatment fungal keratitis is respectively organized far better than other
Effect；The total effective rate for the treatment of group is apparently higher than each single medicinal material group total effective rate sum；It follows that the therapeutic effect for the treatment of group
It it is the mutual synergistic result of each single medicinal material.
Model case favour, female, 25 years old, people from changzhou.Patient removes hospital admission, occurs corneal ulcer, eye in a couple of days
There are light moderate pain, photophobia, the irritation such as shed tears in portion.It is diagnosed as eyes fungal keratitis.Take Chinese medicine preparation of the present invention
Treatment, after taking 1 course for the treatment of, patient's subjective symptoms alleviates, and after inspection, corneal ulcer heals substantially, empyema by faint yellow transfer to white
Color, after continuing to take 1 course for the treatment of, the state of an illness is fully recovered, and follows up a case by regular visits to without recurrence after 1 year.
When patient is followed up a case by regular visits to by applicant, wherein there are 5 example patient reflections, after taking the Chinese medicine preparation of the present invention, not only
Fungal keratitis has obtained effective treatment, and the anaphylaxis often shown effect also disappears.3 example patients are had to say " every time
After entering the woods, arising that skin allergy, play pimple, itches in pole；After the Chinese medicine preparation taking the present invention, above existing
As disappearing ".Another 2 patient's readmes " are eaten shrimp at ordinary times, during oxya chinensis, pain of itching can be occurred, occur red lump subsequently in 10-20 minute
Carbuncle, sensation skin has hotness, and its pain is unbearably；After the Chinese medicine preparation taking the present invention, not only cure fungal keratitis,
And when they eat shrimp again, during oxya chinensis, anaphylaxis does not occurs ".After obtaining this information, we utilize in the present invention
30 example autopaths and 20 examples were had allergies patient to treat by medicine preparation immediately, 30 example autopaths take medicine after 15-30
Recovering normal in minute, 20 examples had allergies patient to carry out allergic condition stimulation after taking medicine, and anaphylaxis did not occurred；Follow up a case by regular visits to three
Year, all there is not anaphylaxis in above patient.
It follows that take the Chinese medicine preparation of the present invention, not only treatment fungal keratitis is evident in efficacy, and to skin
Anaphylactic disease has elimination effect, clinic popularization and application.
Claims (2)
1. the Chinese medicine preparation treating fungal keratitis, it is characterised in that this Chinese medicine preparation is by the Chinese medicine of following weight portion
Make: Folium Lagerstroemiae Indicae 7-11 part, Rhizoma Ligustici 10-16 part, Herba Arenariae Serpyllifoliae 10-18 part, Ramulus et Folium Psychotriae Serpentis 30-40 part, unrooted 60-80 part, sweet
Grass 10-16 part.
A kind of Chinese medicine preparation treating fungal keratitis, it is characterised in that this Chinese medicine preparation is
Be made up of the Chinese medicine of following weight portion: Folium Lagerstroemiae Indicae 9 parts, Rhizoma Ligustici 13 parts, Herba Arenariae Serpyllifoliae 14 parts, Ramulus et Folium Psychotriae Serpentis 35 parts, unrooted 70 parts,
13 parts of Radix Glycyrrhizae.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610664999.9A CN106138486A (en) | 2016-08-05 | 2016-08-05 | A kind of Chinese medicine preparation treating fungal keratitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610664999.9A CN106138486A (en) | 2016-08-05 | 2016-08-05 | A kind of Chinese medicine preparation treating fungal keratitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106138486A true CN106138486A (en) | 2016-11-23 |
Family
ID=57330868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610664999.9A Withdrawn CN106138486A (en) | 2016-08-05 | 2016-08-05 | A kind of Chinese medicine preparation treating fungal keratitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106138486A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103251725A (en) * | 2012-02-15 | 2013-08-21 | 北京以岭药业有限公司 | Application of Chinese medicinal composition in preparation of drugs treating keratitis |
| CN103505562A (en) * | 2013-09-17 | 2014-01-15 | 许东 | Traditional Chinese medicine for treating keratitis |
-
2016
- 2016-08-05 CN CN201610664999.9A patent/CN106138486A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103251725A (en) * | 2012-02-15 | 2013-08-21 | 北京以岭药业有限公司 | Application of Chinese medicinal composition in preparation of drugs treating keratitis |
| CN103505562A (en) * | 2013-09-17 | 2014-01-15 | 许东 | Traditional Chinese medicine for treating keratitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101444611B (en) | Traditional Chinese medicine composition for treating lumbocrural pain and lumbar intervertebral disc protrusion and preparation method thereof | |
| CN104906220B (en) | A kind of Chinese medicine for treating herpes zoster and herpes simplex keratitis | |
| CN1160091C (en) | Medicine for treating ophthalmopathy | |
| CN104524174A (en) | Traditional Chinese medicine composition for treating rheumatic arthralgia and preparation method thereof | |
| CN100490865C (en) | Kidney-nourishing gout-treating capsule | |
| CN106334024A (en) | Traditional Chinese medicine preparation for treating lower extremity thrombophlebitis | |
| CN106138486A (en) | A kind of Chinese medicine preparation treating fungal keratitis | |
| CN108295168B (en) | Traditional Chinese medicine composition for treating post-stroke depression | |
| CN105998843A (en) | Traditional Chinese medicine preparation for treating recurring type dental ulcers | |
| CN105362533A (en) | Nursing lacrimal passage flushing fluid for infantile dacryocystitis and preparation method of flushing fluid | |
| CN1136870C (en) | Medicine for treating rheumatism | |
| CN107158188A (en) | A kind of Chinese medicine preparation for promoting fractures and bone injuries to heal | |
| CN108379327A (en) | A kind of anaesthetic and its preparation process for treating nose-nasosinusitis | |
| CN106138246A (en) | A kind of Chinese medicine preparation treating Anchylosis | |
| CN106177038A (en) | A kind of Chinese medicine preparation treating recurrent oral ulceration | |
| CN107157972A (en) | It is a kind of to reduce the medicine of alotec aerosol clinical side effects | |
| CN102552746B (en) | Traditional Chinese medicine pediluvium composition for treating squamous keratotic type beriberi | |
| CN106361853A (en) | Traditional Chinese medicine preparation for treating liver-and-stomach-dampness-heat chronic gastritis | |
| CN106236958A (en) | A kind of Chinese medicine preparation treating viral keratitis | |
| CN101057915A (en) | Capsule for nourishing kidney and treating rheumatalgia | |
| CN106309855A (en) | Traditional Chinese medicine preparation for treating periodontitis | |
| CN106236956A (en) | A kind of Chinese medicine preparation treating fungal keratitis | |
| CN1225271C (en) | Medicine for curing hyperplasia disease of mamary glands | |
| CN107693614A (en) | A kind of Chinese medicine preparation for treating syndrome of qi stagnation and blood stasis intestinal tuberculosis | |
| CN106177355A (en) | A kind of Chinese medicine preparation treating fracture swelling |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20161123 |